Trial Profile

An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mezagitamab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide; Pomalidomide
Indications Multiple myeloma; Smoldering multiple myeloma
Focus Adverse reactions
Sponsors Takeda Oncology

05 Feb 2025 Planned End Date changed from 23 Feb 2025 to 31 Mar 2026.
05 Feb 2025 Planned primary completion date changed from 23 Feb 2025 to 31 Mar 2026.
29 Apr 2024 Planned End Date changed from 23 Feb 2024 to 23 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com